August 2017

FDA: Lutathera Action Date Set for Late January 2018
news

Advanced Accelerator Applications S.A. (AAA) has announced that the Food and Drug Administration (FDA), in the United States, has accepted and considered complete the resubmission of the New Drug Application (NDA) for its investigational drug lutetium Lu 177 dotatate (Lutathera).  Lutathera is the brand name for the radiologic used in Peptide Receptor Radionuclide Therapy (PRRT). The FDA has set an action date of Jan 26, 2018. AAA is attempting to obtain U.S.

Worldwide NET Cancer Day
action

Recently, while aimlessly browsing on the Internet, I discovered a website that was trying to encourage Google to make November 10th a Google Doodle to help raise awareness of NET Cancer Day. I don’t recall that happening, ever. I figure it’s August, so, now is the time to start getting these types of requests in place. Below, see my sample email that I sent to proposals@google.com to suggest November 10th as NET

Treatment combinations for pancreatic neuroendocrine tumors
news

A new paper has recently been released in Digestion: International Journal of Gastroenterology that reviewed previously reported European trials. These trials specifically aimed at the treatment of advanced pancreatic neuroendocrine tumors outlined several combinations of chemotherapy drugs used to help with progression free survival (PFS). Pancreatic neuroendocrine tumors (PNETS) are still relatively rare in the umbrella of all gastroenteropancreatic tumors (GEP-NETS or just NETS) and certainly amongst pancreatic lesions in general.